

Datasheet: MCA6088

Description:	HUMAN ANTI TNF ALPHA (ADALIMUMAB BIOSIMILAR)				
Specificity:	TNF ALPHA				
Format:	Purified				
Product Type:	Monoclonal Antibody				
Clone:	D2E7				
lsotype:	lgG1				
Quantity:	0.2 mg				

Product Details

Applications	from testing within our labor the originators. Please refer	ed publications or person ted for further information	cations. This information is derived ns or personal communications from r information. For general protocol					
	recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .							
	ELISA	Yes	No	Not Determined	Suggested Dilution			
	Where this product has not exclude its use in such proc recommended that the user negative/positive controls.	edures. S	uggested v	vorking dilutions are give	en as a guide only. It is			
Target Species	Human							
Product Form	Human IgG1 (kappa) antibo	ody - liquid	I					
Preparation	Purified recombinant IgG pr line	epared by	∕ affinity chi	romatography on Protein	A from a mammalian cell			
Buffer Solution	Phosphate buffered saline							
Preservative Stabilisers	0.02% Proclin 300							
Approx. Protein Concentrations	IgG concentration 1.0 mg/m	l						
Immunogen	Human TNFα							
Specificity	Human Anti-TNF alpha antibody, clone D2E7 is a research grade biosimilar of the monoclonal antibody drug adalimumab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic adalimumab antibody clone D2E7.							
	Human Anti-TNF alpha antibody, clone D2E7 is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-adalimumab antibodies, for example <u>HCA202</u> and <u>HCA203</u> . It can also be used as capture and detection reagent in an anti-drug							

antibody (ADA) bridging ELISA, with an anti-adalimumab antibody in IgG1 format as reference standard, for example <u>HCA203</u>, <u>HCA204</u> or <u>HCA205</u>, or an anti-adalimumab antibody in IgE format as reference standard, for example <u>HCA271</u>.

The therapeutic antibody adalimumab (Humira) is a fully human monoclonal antibody (IgG1 kappa) approved for the treatment of ankylosing spondylitis, Crohn's disease, psoriasis and several forms of arthritis. The antibody is specific for TNF alpha, and acts by blocking the activation of TNF receptors by TNF alpha. This inactivation down-regulates the inflammatory reactions associated with autoimmune diseases.

This product is NOT FOR THERAPEUTIC USE.

View a summary of supporting anti-adalimumab antibody products

Purity	>98% by SDS PAGE
Storage	Store at +4°C or at -20°C if preferred.
	Storage in frost-free freezers is not recommended.
	This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature
	the antibody. Should this product contain a precipitate we recommend microcentrifugation before
	use
Guarantee	12 months from date of despatch
Health And Safety	Material Safety Datasheet documentation #20463 available at:
Information	20463: https://www.bio-rad-antibodies.com/uploads/MSDS/20463.pdf
Licensed Use	For in vitro research purposes only. Research grade biosimilar. Not for use in therapeutic or
	diagnostic procedures for humans or animals.
Regulatory	For research purposes only

Related Products

Recommended Useful Reagents

HUMAN ANTI ADALIMUMAB (HCA202) HUMAN ANTI ADALIMUMAB (HCA203) HUMAN ANTI ADALIMUMAB (HCA204) HUMAN ANTI ADALIMUMAB (HCA204P) HUMAN ANTI ADALIMUMAB (HCA205) HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX) (HCA206) HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX) (HCA207) HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX) (HCA207) HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX) (HCA231) HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX) (HCA232) HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX) (HCA232) HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX) (HCA232) HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX):HRP (HCA232P) HUMAN ANTI ADALIMUMAB (HCA271) HISPEC ASSAY DILUENT (BUF049A) LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK001P)

North & South	Tel: +1 800 265 7376	Worldwide	Tel: +44 (0)1865 852 700	Europe	Tel: +49 (0) 89
America	Fax: +1 919 878 3751		Fax: +44 (0)1865 852 739		Fax: +49 (0) 8
	Email: antibody_sales_us@	bio-rad.com	Email: antibody_sales_uk@bio	-rad.com	Email: antibody

Fel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com 'M373145:200827'

Printed on 27 Aug 2020

© 2020 Bio-Rad Laboratories Inc | Legal | Imprint